Hemophilia gene therapy: update. Curr Opin Hematol 2002 Sep;9(5):430-6
Date
08/13/2002Pubmed ID
12172462DOI
10.1097/00062752-200209000-00007Scopus ID
2-s2.0-0036341573 (requires institutional sign-in at Scopus site) 10 CitationsAbstract
Gene transfer is an exciting and potentially important treatment approach for hemophilia A and B. Four phase I clinical trials of the safety of gene transfer in hemophilia A or B have been completed and two more trials are currently underway. The results of these trials indicate that gene transfer in hemophilia with the vectors and doses used is safe and well tolerated. Efforts continue to understand the basic biology and improve the efficiency of gene transfer.
Author List
Monahan PE, White GC 2ndAuthor
Gilbert C. White MD Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AnimalsClinical Trials as Topic
Factor IX
Factor VIII
Genetic Therapy
Genetic Vectors
Hemophilia A
Hemophilia B
Humans









